Myfortic (Mycophenolic Acid)

Mycophenolic acid selectively blocks the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for the de novo synthesis of guanosine nucleotides. This blockade depletes guanosine pools needed for DNA synthesis, thereby suppressing the proliferation of activated T‑ and B‑lymphocytes that drive immune‑mediated graft rejection.

The dosage of Myfortic is individualized by the prescribing physician based on the type of transplant, patient weight, renal function, and concomitant immunosuppressants. Only a qualified healthcare professional should determine the appropriate dose and schedule for each patient.

Myfortic is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided in pregnant women unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug is excreted in milk and may affect the infant.

To request Myfortic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both Myfortic (mycophenolate sodium) and azathioprine are antimetabolite immunosuppressants, but Myfortic more selectively inhibits lymphocyte proliferation by targeting IMPDH, often resulting in a more predictable efficacy profile. Azathioprine has a broader mechanism and may be associated with different toxicity patterns, such as hepatotoxicity and hypersensitivity, making Myfortic a preferred option in many transplant protocols.

Myfortic tablets should be stored at temperatures below 25 °C, in their original container, protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Myfortic is taken orally, usually as whole tablets swallowed with water. It is typically administered twice daily, but the exact schedule should follow the prescribing clinician’s instructions. Food may affect absorption, so patients should follow any specific guidance regarding meals.

The most serious adverse effects include severe leukopenia or neutropenia, which can predispose to life‑threatening infections, as well as opportunistic infections such as cytomegalovirus, and rare cases of hepatic toxicity or malignancy. Regular monitoring of blood counts and liver function is essential to detect these risks early.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolate sodium or any of its excipients, in pregnant women unless absolutely necessary, and in individuals with severe, uncontrolled infections. Caution is also advised for patients with significant renal impairment, as dose adjustments may be required.